Prognostic Impact of Concomitant Genomic Alterations in FGFR2-Positive Cholangiocarcinoma Treated With Pemigatinib.

Liver Int · 2026 · PMC13396969 · PMID 42494243

Europe PMC DOI

hedged sentence

0.2000

closest p · 4.0× alpha

0.2000

boldest claim

The sentences

showed a trendp = 0.2not close (p > 0.1)

While CDKN2A loss showed a trend towards shorter PFS (4.9 vs. 9.7 months; p = 0.2), CDKN2B loss was significantly associated with worse outcomes (PFS 4.8 vs. 11.0 months; p = 0.03).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.